The Centre for Applied Genomics (Reuter, Walker, Thiruvahindrapuram, Whitney, Yuen, Trost, Paton, Pereira, Herbrick, Wintle, Merico, Howe, MacDonald, Lu, Nalpathamkalam, Sung, Wang, Patel, Pellecchia, J. Wei, Strug, Bell, Kellam, Mahtani, Hosseini, Fiume, Marshall, Buchanan, Scherer); Divisions of Clinical Pharmacology and Toxicology (I. Cohn), or Clinical, and Metabolic Genetics (Sondheimer, Weksberg, Shuman, Bowdin, Meyn, Monfared), The Hospital for Sick Children; Departments of Paediatrics (Sondheimer, R. Cohn) and Molecular Genetics (Yuen, Weksberg, Shuman, R. Cohn, Ellis, Meyn), University of Toronto; Deep Genomics Inc. (Merico); Department of Psychiatry (Bassett), University Health Network and Centre for Addiction and Mental Health, University of Toronto; Li Ka Shing Knowledge Institute (Bombard), St. Michael's Hospital; Institute of Health Policy, Management and Evaluation (Bombard), University of Toronto; Centre for Genetic Medicine (Stavropoulos, Bowdin, Ray, Monfared); Molecular Genetics Laboratory (Stavropoulos, Ray, Marshall), Division of Genome Diagnostics, Paediatric Laboratory Medicine; Developmental and Stem Cell Biology (Hildebrandt, W. Wei, Romm, Pasceri, Ellis); Ted Rogers Cardiac Genome Clinic (Hosseini); Cytogenetics Laboratory (Joseph-George), Division of Genome Diagnostics, Paediatric Laboratory Medicine, The Hospital for Sick Children; Departments of Biochemistry and Laboratory Medicine, and Pathobiology (Keeley), University of Toronto; DNAstack (Cook, Fiume); McLaughlin Centre (Lee, Scherer), University of Toronto; Medcan Health Management Inc. (Davies, Hazell); Dalla Lana School of Public Health (Szego), Department of Family and Community Medicine, and The Joint Centre for Bioethics, University of Toronto; Centre for Clinical Ethics (Szego), St. Joseph's Health Centre, Toronto, Ont.
CMAJ. 2018 Feb 5;190(5):E126-E136. doi: 10.1503/cmaj.171151.
The Personal Genome Project Canada is a comprehensive public data resource that integrates whole genome sequencing data and health information. We describe genomic variation identified in the initial recruitment cohort of 56 volunteers.
Volunteers were screened for eligibility and provided informed consent for open data sharing. Using blood DNA, we performed whole genome sequencing and identified all possible classes of DNA variants. A genetic counsellor explained the implication of the results to each participant.
Whole genome sequencing of the first 56 participants identified 207 662 805 sequence variants and 27 494 copy number variations. We analyzed a prioritized disease-associated data set ( = 1606 variants) according to standardized guidelines, and interpreted 19 variants in 14 participants (25%) as having obvious health implications. Six of these variants (e.g., in or mosaic loss of an X chromosome) were pathogenic or likely pathogenic. Seven were risk factors for cancer, cardiovascular or neurobehavioural conditions. Four other variants - associated with cancer, cardiac or neurodegenerative phenotypes - remained of uncertain significance because of discrepancies among databases. We also identified a large structural chromosome aberration and a likely pathogenic mitochondrial variant. There were 172 recessive disease alleles (e.g., 5 individuals carried mutations for cystic fibrosis). Pharmacogenomics analyses revealed another 3.9 potentially relevant genotypes per individual.
Our analyses identified a spectrum of genetic variants with potential health impact in 25% of participants. When also considering recessive alleles and variants with potential pharmacologic relevance, all 56 participants had medically relevant findings. Although access is mostly limited to research, whole genome sequencing can provide specific and novel information with the potential of major impact for health care.
加拿大个人基因组计划是一个综合的公共数据资源,整合了全基因组测序数据和健康信息。我们描述了在最初招募的 56 名志愿者队列中发现的基因组变异。
志愿者经过资格筛选并同意开放数据共享。我们使用血液 DNA 进行全基因组测序,并确定了所有可能的 DNA 变异类型。一位遗传咨询师向每位参与者解释了结果的含义。
对前 56 名参与者的全基因组测序共鉴定出 207662805 个序列变异和 27494 个拷贝数变异。我们根据标准化指南分析了一个优先考虑的疾病相关数据集(=1606 个变异),并解释了 14 名参与者(25%)的 19 个变异具有明显的健康影响。其中 6 个变异(例如,在或 X 染色体的镶嵌性缺失)是致病性或可能致病性的。7 个是癌症、心血管或神经行为疾病的风险因素。其他 4 个变异——与癌症、心脏或神经退行性表型相关——由于数据库之间的差异,仍然具有不确定性。我们还发现了一个大的结构性染色体异常和一个可能的致病性线粒体变异。有 172 个隐性疾病等位基因(例如,5 个人携带囊性纤维化的突变)。药物基因组学分析显示每个个体还有另外 3.9 个潜在相关基因型。
我们的分析确定了 25%的参与者中具有潜在健康影响的一系列遗传变异。当还考虑隐性等位基因和具有潜在药物相关性的变异时,所有 56 名参与者都有医学相关的发现。尽管主要是限于研究,全基因组测序可以提供具有潜在重大影响的具体和新颖的健康信息。